Paradigm Biopharmaceuticals Ltd. (AU:PAR)

ASX:PAR

PAR

Paradigm Biopharmaceuticals

RESEARCH TOOLSreports

Paradigm Biopharmaceuticals (PAR) Price & Analysis

Compare

40 Followers

PAR Stock Chart & Stats

AU$0.33

-AU$0.03(-5.32%)

At close: Jan 09 4:00 PM EST

AU$0.33

-AU$0.03(-5.32%)

Day’s Range― - ―

52-Week RangeAU$0.24 - AU$0.48

Previous CloseN/A

Volume3.26M

Average Volume (3M)841.61K

Market Cap

AU$113.45M

Enterprise ValueAU$97.58M

Total Cash (Recent Filing)AU$14.66M

Total Debt (Recent Filing)AU$1.01M

Price to Earnings (P/E)―

Beta2.67

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding444,908,140

10 Day Avg. Volume720,106

30 Day Avg. Volume841,610

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)4.53

Price to Sales (P/S)1840.42

P/FCF Ratio-6.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.1

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Liquidity BufferExtremely low debt reduces refinancing and interest-rate risk, giving management structural flexibility to fund R&D or operations from the balance sheet. Over a 2–6 month horizon this lowers bankruptcy and liquidity risk and supports continuity of strategic programs.

Narrowing Net Loss (FY2025)A materially smaller FY2025 net loss signals operating improvement or cost discipline that can persist through the next several quarters. This improves runway dynamics, reduces near-term dilution pressure and indicates management progress toward stabilizing operations.

Reduced Cash Burn Vs FY2024A sharp reduction in cash outflow is a durable positive: it extends runway and lowers reliance on immediate external financing. If sustained, improved burn rate enables focused R&D investments and gives management time to execute long-term strategy without urgent capital raises.

Bears Say

Minimal And Volatile RevenueVery small, inconsistent revenue reflects limited commercial traction and lack of scale. Over months this constrains margin expansion, weakens predictability of cash generation, and increases the probability the firm must rely on dilutive financing to fund ongoing operations.

Persistent Negative Cash FlowChronic negative operating and free cash flow means the business does not self-fund growth and must continually access capital markets. Structurally, this raises dilution risk, limits strategic optionality and can force cuts to R&D or commercialization if funding tightens.

Declining Equity And Negative ROEMaterial equity erosion and deeply negative ROE signal that cumulative losses are depleting shareholder value. Over a multi-month horizon this weakens financial flexibility, impairs investor confidence, and can restrict access to favourable capital or partnership terms.

Paradigm Biopharmaceuticals News

Paradigm Expands Global Phase 3 Osteoarthritis Trial to Hong Kong and Moldova

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement. Paradigm Biopharmaceuticals has activated a new clinical trial site...

8d ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for 5.65 Million New Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an announcement. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

11d ago

Paradigm Biopharmaceuticals Widens Half-Year Loss on Intensified Phase 3 Investment

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals reported a net loss before tax of...

29d ago

Paradigm Biopharmaceuticals Updates Market on Director Paul Rennie’s Equity Holdings

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an update. Paradigm Biopharmaceuticals has disclosed changes in director Paul Rennie’s...

1M ago

Paradigm Biopharmaceuticals Updates Market on Director Option Lapse

The latest update is out from Paradigm Biopharmaceuticals ( ($AU:PAR) ). Paradigm Biopharmaceuticals has disclosed a change in...

1M ago

Paradigm’s PPS Shows Sustained Clinical and Structural Benefits in Canine Osteoarthritis Study

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an announcement. Paradigm Biopharmaceuticals announced that a Paradigm-supported study of pentosan...

1M ago

Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug

Paradigm Biopharmaceuticals ( ($AU:PAR) ) just unveiled an update. Paradigm Biopharmaceuticals has signed a binding term sheet with...

2M ago

Paradigm Biopharmaceuticals Director Converts Options Into Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has disclosed a change in the interests...

2M ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an update. Paradigm Biopharmaceuticals has applied to the ASX for quotation...

2M ago

Paradigm Biopharmaceuticals Seeks ASX Quotation for Additional Ordinary Shares

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an update. Paradigm Biopharmaceuticals has applied for quotation on the ASX...

2M ago

PAR FAQ

What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?

Paradigm Biopharmaceuticals Ltd. lowest share price was AU$0.24 and its highest was AU$0.48 in the past 12 months.

What is Paradigm Biopharmaceuticals Ltd.’s market cap?

Paradigm Biopharmaceuticals Ltd.’s market cap is AU$113.45M.

When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?

Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 154 days.

How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?

Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.056.

Is Paradigm Biopharmaceuticals Ltd. overvalued?

According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Paradigm Biopharmaceuticals Ltd. pay dividends?

Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.

What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?

Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?

Paradigm Biopharmaceuticals Ltd. has 444,908,140 shares outstanding.

What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?

Paradigm Biopharmaceuticals Ltd. reported an EPS of -AU$0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.852%.

Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:PAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Paradigm Biopharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-265.55%

Trailing 12-Months

Asset Growth

-29.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.